Bausch Health Reports Mixed 2025 Results Amid Strategic Moves — Bausch Health Companies Inc.

Event summary

Bausch Health reported $2.80 billion in Q4 2025 revenue, up 9% YoY, with full-year revenue reaching $10.27 billion, a 7% increase.
The company completed the acquisition of Shibo's aesthetics distribution business in China on December 1, 2025.
Bausch Health executed a $1.7 billion debt exchange offer in Q4 2025 and $9.6 billion in total refinancing for the full year.
Adjusted EBITDA attributable to Bausch Health rose 13% in Q4 2025 to $1.05 billion and 7% for the full year to $3.54 billion.
The company initiated a Phase 3 trial for Larsucosterol (Epigenetic Modulator) in January 2026, following FDA Breakthrough Therapy Designation.

The big picture

Bausch Health's 2025 results reflect a mixed performance with revenue growth offset by a GAAP net loss in Q4 due to goodwill impairment. The company's strategic moves, including acquisitions and debt refinancing, aim to strengthen its balance sheet and expand its global footprint. The initiation of a Phase 3 trial for Larsucosterol underscores its focus on innovative treatments, while the acquisition of Shibo's business highlights its commitment to the aesthetics market in China. The company's ability to sustain operational efficiency and manage regulatory dynamics will be critical in the coming years.

What we're watching

Regulatory Dynamics: The impact of FDA Breakthrough Therapy Designation for Larsucosterol on Bausch Health's pipeline and future revenue streams.
Market Expansion: The success of the newly acquired aesthetics distribution business in China and its contribution to global revenue growth.
Debt Management: The effectiveness of Bausch Health's debt refinancing strategy in extending maturities and improving financial flexibility.